ciprofloxacin has been researched along with cytarabine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Abdulhameed, MD; Compton, JR; Friedlander, AM; Hershfield, JR; Hu, X; Jadhav, A; Leary, DH; Legler, PM; Marchand, CL; Robertson, KL; Wallqvist, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Donnelly, JP; Muytjens, HL; Novakova, IR; Weers-Pothoff, G | 1 |
| Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M | 1 |
| Herbrecht, R; Jarfaut, A; Levêque, D; Santucci, R | 1 |
1 review(s) available for ciprofloxacin and cytarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for ciprofloxacin and cytarabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
3-substituted indole inhibitors against Francisella tularensis FabI identified by structure-based virtual screening.
Topics: Amino Acid Sequence; Animals; Bacterial Proteins; Cell Line, Tumor; Cell Survival; Computational Biology; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enzyme Inhibitors; Francisella tularensis; Humans; Indoles; Kinetics; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutation; Protein Binding; Protein Structure, Tertiary; Sequence Homology, Amino Acid; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Bacteraemia caused by Stomatococcus mucilaginosus in a granulocytopenic patient with acute lymphocytic leukaemia.
Topics: Adult; Agranulocytosis; Amsacrine; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sepsis | 1989 |
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ecthyma; Female; gamma-Globulins; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pseudomonas aeruginosa; Pseudomonas Infections; Scalp; Sepsis; Treatment Outcome | 2004 |
Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bicarbonates; Bleomycin; Ciprofloxacin; Crystallization; Cyclophosphamide; Cytarabine; Diarrhea; Doxorubicin; Drug Eruptions; Drug Interactions; Etoposide; Female; Fluid Therapy; Fungemia; Humans; Hydrogen-Ion Concentration; Ifosfamide; Lymphoma, B-Cell; Mediastinal Neoplasms; Metabolic Clearance Rate; Methotrexate; Mucositis; Pancytopenia; Prednisone; Solubility; Urine; Vindesine | 2013 |